GlaxoSmithKline Pharmaceuticals Shares Rise by 2.21% in Today's Session

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

During today's session, GlaxoSmithKline Pharmaceuticals saw its shares climb by 2.21%, with the price reaching Rs 3187.00. This increase marks a notable movement for the stock, which is part of the NIFTY MIDCAP 150 index.

The revenue for GlaxoSmithKline Pharmaceuticals has shown consistent performance over the recent quarters. In March 2025, the company reported revenue of Rs 974.37 Cr, slightly up from Rs 949.42 Cr in December 2024. The net profit also saw an increase, with Rs 262.87 Cr in March 2025 compared to Rs 229.88 Cr in December 2024. The Earnings Per Share (EPS) stood at Rs 15.52 in March 2025, compared to Rs 13.57 in December 2024.

Looking at the annual figures, GlaxoSmithKline Pharmaceuticals has demonstrated substantial growth. The revenue increased from Rs 3,453.71 Cr in 2024 to Rs 3,749.21 Cr in 2025. The net profit also saw a significant rise, from Rs 589.96 Cr in 2024 to Rs 927.58 Cr in 2025. The EPS increased from Rs 41.14 in 2024 to Rs 54.52 in 2025. The Book Value Per Share (BVPS) also rose from Rs 104.93 in 2024 to Rs 115.18 in 2025. The company's Return on Equity (ROE) stood at 47.53% in 2025, compared to 33.42% in the previous year. The Debt to Equity ratio remained stable at 0.00.

The annual income statement shows a growth in sales from Rs 3,453 Cr in March 2024 to Rs 3,749 Cr in March 2025. The total income increased from Rs 3,576 Cr to Rs 3,895 Cr during the same period. The total expenditure also rose from Rs 2,758 Cr to Rs 2,633 Cr. The Earnings Before Interest and Taxes (EBIT) increased from Rs 817 Cr to Rs 1,261 Cr. The net profit increased from Rs 589 Cr to Rs 927 Cr.

The quarterly income statement shows sales of Rs 974 Cr in March 2025, compared to Rs 949 Cr in December 2024. The total income rose from Rs 984 Cr to Rs 1,015 Cr. The total expenditure increased from Rs 676 Cr to Rs 655 Cr. The EBIT increased from Rs 308 Cr to Rs 359 Cr. The net profit also saw an increase, from Rs 229 Cr to Rs 262 Cr.

According to a Moneycontrol analysis as of 2025-05-21, the sentiment for GlaxoSmithKline Pharmaceuticals is very bullish.

The cash flow statement indicates that the net cash flow from operating activities was Rs 1,289 Cr in March 2025, compared to Rs 582 Cr in the previous year. The net cash flow from investing activities was -Rs 45 Cr, and from financing activities was -Rs 769 Cr. Overall, the net cash flow stood at Rs 474 Cr.

The equities and liabilities section of the balance sheet shows that the share capital remained constant at Rs 169 Cr. The reserves and surplus increased from Rs 1,617 Cr to Rs 1,781 Cr. The total liabilities increased from Rs 3,556 Cr to Rs 4,108 Cr. On the assets side, the fixed assets remained relatively stable at Rs 297 Cr, while the current assets increased from Rs 2,798 Cr to Rs 3,409 Cr. The total assets also increased from Rs 3,556 Cr to Rs 4,108 Cr.

Key financial ratios for GlaxoSmithKline Pharmaceuticals include a basic EPS of Rs 54.52 in March 2025, compared to Rs 41.14 in the previous year. The dividend per share stood at Rs 54.00 in March 2025, compared to Rs 32.00 in the previous year. The return on net worth/equity was 47.53%, and the debt to equity ratio was 0.00.

With GlaxoSmithKline Pharmaceuticals' shares trading at Rs 3187.00, the stock has shown a positive movement, driven by consistent financial performance and very bullish market sentiment.